Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial
The purpose of this study is to evaluate the efficacy of Eslicarbazepine acetate QD at doses of 800 mg and 1200 mg compared with placebo as an adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period. (Enrolling in Jacksonville, FL)
Keywordseslicarbazepine acetate, seizures, convulsions
Principal InvestigatorSHACHIE ARANKE
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.